Etoposide for epidemic Kaposi's sarcoma: A phase II study

Piet J.M. Bakker*, Sven A. Danner, Joep M.A. Lange, Kees H.N. Veenhof

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.

Original languageEnglish
Pages (from-to)1047-1048
Number of pages2
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number6
Publication statusPublished - Jun 1988

Cite this